Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep-Oct;22(5):338-343.
doi: 10.5863/1551-6776-22.5.338.

Improving Palivizumab Compliance rough a Pharmacist-Managed RSV Prevention Clinic

Jennifer W Chow  1 , Michael F Chicella  1 , Anthony M Christensen  1 , Carolyn S Moneymaker  1 , John Harrington  1 , James E Dice  1
Affiliations

Improving Palivizumab Compliance rough a Pharmacist-Managed RSV Prevention Clinic

Jennifer W Chow et al. J Pediatr Pharmacol Ther. 2017 Sep-Oct.

Abstract

Objectives: Palivizumab is a monoclonal antibody approved for the prevention of serious lower respiratory tract infections caused by respiratory syncytial virus (RSV) in high-risk pediatric patients. While palivizumab is more effective if used correctly, compliance with the monthly dosing is suboptimal. We established a pharmacist-managed RSV prevention clinic in an effort to improve compliance. The primary objective of this study was to determine the impact of a pharmacist-managed RSV prevention clinic on palivizumab compliance.

Methods: A chart review was performed. Patients who received palivizumab between September 2009 and April 2012 were identified. Compliance was determined as the number of patients who received eligible doses at 28- to 30-day intervals, consecutively.

Results: One hundred seventy-two patients received at least 1 dose of palivizumab. An average of 92% of patients who received at least 1 dose subsequently received all doses of palivizumab during the RSV season. Of those, 88% received all eligible doses in consecutive 28-to 30-day intervals.

Conclusion: A pharmacist-managed RSV prevention clinic can assist physicians in the prevention of RSV by increasing compliance with palivizumab dosing.

Keywords: compliance; infant; palivizumab; respiratory syncytial viruses.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors declare no conflicts or financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employment, gifts and honoraria. Michael Chicella had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References

    1. Shay DK, Holman RC, Newman RD, . et al. Bronchiolitis-associated hospitalizations among US children, 1980–1996. JAMA. 1999; 282 15: 1440– 1446. - PubMed
    1. Leader S, Kohlhase K.. Respiratory syncytial virus-coded pediatric hospitalizations, 1997–1999. Pediatr Infect Dis J. 2002; 21 7: 629– 632. - PubMed
    1. Leader S, Kohlhase K.. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr. 2003; 143 5 suppl: S127– S132. - PubMed
    1. Glezen WP, Taber LH, Frank AL, . et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986; 140 6: 543– 546. - PubMed
    1. Holberg CJ, Wright AL, Martinez FD, . et al. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am J Epidemiol. 1991; 133 11: 1135– 1151. - PubMed

LinkOut - more resources